Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25N5O10.ClH |
| Molecular Weight | 531.901 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=O)NC2=O)C(O)=O)[C@H](O)C3=NC=C(O)C=C3
InChI
InChIKey=HLFYQXGEGXXXIQ-FNRJKXLQSA-N
InChI=1S/C20H25N5O10.ClH/c1-7(13(28)9-3-2-8(26)6-22-9)11(21)17(31)24-12(19(32)33)16-14(29)15(30)18(35-16)25-5-4-10(27)23-20(25)34;/h2-7,11-16,18,26,28-30H,21H2,1H3,(H,24,31)(H,32,33)(H,23,27,34);1H/t7-,11-,12-,13-,14-,15+,16+,18+;/m0./s1
Nikkomycin Z is an antifungal drug that inhibits chitin synthase. It has been reported that it inhibits chitin synthases (Chs) 1 and 3, but not 2, of Saccharomyces cerevisiae. Later it was found that nikkomycin Z inhibited all three Chs isozymes of Candida albicans (CaChs). The IC(50) value for CaChs1 is 15 uM, for CaChs2 0.8 uM, and for CaChs3 13 uM. Nikkomycin Z is under development as an orphan product for treatment of coccidioidomycosis. Nikkomycin Z has been used in trials studying the treatment and basic science of Coccidioidomycosis. In February 2006, nikkomycin z was designated as an orphan drug for the treatment of Coccidioidomycosis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. | 2000-09 |
|
| Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. | 2000-02 |
|
| In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. | 1999-06 |
|
| Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. | 1998-09 |
|
| Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. | 1992-06 |
|
| Synthesis and biological evaluation of dipeptidyl and tripeptidyl polyoxin and nikkomycin analogues as anticandidal prodrugs. | 1991-01 |
|
| Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans. | 1986-03 |
Patents
Sample Use Guides
Safety and pharmacokinetics of nikkomycin Z were evaluated in healthy male subjects following single, rising oral doses ranging from 250 mg to 2,000 mg. Pharmacokinetics appeared linear over the range of 250 to 500 mg; however, relative bioavailability was about 62 to 70% for the 1,000-mg dose and 42 to 47% for doses between 1,500 and 2,000 mg.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76967378
Created by
admin on Mon Mar 31 18:03:37 GMT 2025 , Edited by admin on Mon Mar 31 18:03:37 GMT 2025
|
PRIMARY | |||
|
09K02O611R
Created by
admin on Mon Mar 31 18:03:37 GMT 2025 , Edited by admin on Mon Mar 31 18:03:37 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
